TASHKENT, Uzbekistan, Nov. 11, 2024 /PRNewswire/ -- Arctech, the world's leading solar tracking and racking solutions provider, announced that it has started the shipment of its signature 1P single-axis solar tracking system SkyLine II for the 320MW photovoltaic project in Buka, Tashkent, Uzbekistan. This shipment has been initiated within only half a month following the project's signing, demonstrating Arctech's excellence in the supply chain. Furthermore, the utilization of SkyLine II for this project highlights its advanced features that have garnered high praise from clients.
The project is located in Buka, where it faces severe weather conditions including strong winds and heavy snowfall, presenting significant challenges to the installation and operation of the project. However, Arctech's pioneering synchronous multi-point drive mechanism enables horizontal stowing during high wind events, reducing wind pressures on solar panels while leading to up to 2% more energy yield per year.
Considering the heavy snowfall in the region, SkyLine II has been designed with a special snow strategy. This innovative feature facilitates efficient removal of accumulated snow from the panels to one side, ensuring uninterrupted operation of power stations during snowy periods while eliminating the need for manual snow removal. Ultimately, this enhancement optimizes power generation while protecting solar modules from excessive weight caused by snow.
Relying on its efficient global supply chain and local service team, Arctech promptly responded to ensure the smooth progress of the project. Faced with the urgent deadline for the first batch of deliveries, its comprehensive service team swiftly coordinated production and logistics while maintaining effective communication with clients to ensure timely shipment, thereby earning high commendation from customers.
After completion, the project will generate an annual power output of 572,502MWh, resulting in an annual saving of approximately 163,000 tons of standard coal and a reduction of about 45 tons of SO2 emissions and about 448,000 tons of CO2 emissions, effectively alleviating the current power supply shortage in Tashkent and contributing to Uzbekistan's transition towards green energy.
The Arctech team has successfully amassed a robust portfolio of over 2.3GW in Uzbekistan to date. Moving forward, Arctech is dedicated to further contributing to the energy transition in Uzbekistan and beyond through its advanced solar tracking and racking solutions.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Arctech SkyLine II: Revolutionizing the 320MW Uzbek Project with Swift Shipment and Innovative Solar Tracking Solution
HONG KONG, Jan. 2, 2025 /PRNewswire/ -- HKSH Cancer Centre organised the sixth "HKSH Symposium on Advances in Cancer Management" ("The Symposium") which was held on 12 December 2024 at the HKSH Eastern Building. With the theme "Breakthroughs in Cancer Management", the Symposium attracted approximately 800 healthcare professionals from around the globe to participate both in-person and online. As the HKSH Proton Therapy Centre marks its one-year anniversary, being one of over 120 proton therapy facilities worldwide, several experts from HKSH focused on sharing local experiences with Hong Kong's first proton therapy system in treating major cancers such as head and neck cancer, breast cancer, and paediatric cancer. They also explored groundbreaking advancements combining clinical and research cancer treatments, including MR-guided radiotherapy, genomic profiling in cancer for precision medicine, and latest advances in medical therapy for cancers.
Dr. Walton LI, Chief Executive Officer of the HKSH Medical Group ("HKSH") and Medical Superintendent of Hong Kong Sanatorium & Hospital, highlighted in his opening speech, "After nearly two decades of efforts for the proton therapy project, Hong Kong's first proton therapy system officially commenced service in 2023, marking a significant breakthrough in medical technology for Hong Kong, thanks to the concerted efforts of multiple specialty teams. We hope the Symposium provides a platform for experts from different fields to exchange experiences and new knowledge, thereby striving to improve clinical outcomes in cancer treatment." Dr. LI also mentioned that besides providing clinical services and advancing research, HKSH has been collaborating with the Mayo Clinic in Arizona, USA, to offer specialised proton therapy training for oncology specialists, further establishing Hong Kong's role as a cancer medical hub in the Greater China region.
Mr. Wyman LI, Chief Operating Officer of HKSH Medical Group and Director of Hong Kong Sanatorium & Hospital, emphasised in the closing, "With the opening of the HKSH Proton Therapy Centre, HKSH is now equipped with a full range of world-class advanced cancer radiotherapy systems. Our team has carried out approximately 300 proton therapy cases to date, mainly comprising breast cancer and prostate cancer cases, with paediatric patients making up about ten percent. HKSH will continue to steadily develop proton therapy services to implement treatment plans for major cancers, especially focusing on the needs of paediatric cancer patients to minimise treatment side effects and assist in their healthy growth."
HKSH Cancer Centre, following the launch of proton therapy services, is steadily advancing into a new milestone. Now run on Happy Valley and A Kung Ngam campuses, HKSH Cancer Centre will continue to strive for the best experience for our patients throughout the patient journey with multidisciplinary services, ranging from cancer genetics, diagnostics, rehabilitation to counselling to offer high-quality and reliable medical options and services to cancer patients. Looking ahead, HKSH will host the fifth PTCOG Asia Oceania Congress in November 2025, marking the first international particle therapy academic meeting held in Hong Kong. It is anticipated to attract top global experts to explore innovative treatments, further promote and enhance healthcare standards, and bring hope for treatment to cancer patients.
For more information:
Learn more about HKSH Proton Therapy Centre here
Watch our Proton Therapy video series here
For enquiries, please contact:
Corporate Affairs Department, HKSH Medical Group
media@cad.hksh.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
HKSH Symposium on Advances in Cancer Management 2024 Breakthroughs in Cancer Management
